Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up after Novartis or Penn CAR T-cell therapy
NL-OMON58849Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Oct 2019
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of durcabtagene autoleucel in hematopoietic malignancies and Neoplasm, sponsored by Novartis. Primary endpoints: Proportion of patients with new primary or secondary malignancies, Proportion of patients with new serious infections and 4 more. Started Oct 2019; status: recruiting.
02
Drugs
durcabtagene autoleucel
03
Conditions
hematopoietic malignanciesNeoplasm
Beyond the preview
Go deeper on NL-OMON58849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58849.